Top Markets
#1 0G 0G +40.67%
#2 Merlin's Seal BTC Merlin's Seal BTC +37.95%
#3 StonkBroker StonkBroker +34.05%
#4 Useless Coin Useless Coin +33.72%
#5 SAFEcoin SAFEcoin +30.41%
#6 Dogs Dogs +24.40%
#7 Pons Pons +23.19%
#8 rsERG rsERG +22.64%
#9 Zora Zora +22.63%
#10 ICON ICON +21.32%
Coin of the day
0G 0G
設定
言語
日本
通貨
USD
テーマ
Graphite Bio, Inc. Graphite Bio, Inc.

Graphite Bio, Inc.

GRPH
株式のランク #12750
Graphite Bio, Inc. is a clinical-stage gene editing company dedicated to... Graphite Bio, Inc. is a clinical-stage gene editing company dedicated to developing innovative therapeutic solutions for severe and life-threatening illnesses across the United States. Its primary investigational therapy, GPH101, is an autologous, gene-edited hematopoietic stem cell product specifically engineered to directly correct the underlying mutation causing sickle cell disease, thereby restoring normal adult hemoglobin production. The company's pipeline also features GPH201, intended for the treatment of X-linked severe combined immunodeficiency syndrome, and GPH301, an experimental candidate designed to address Gaucher disease, a genetic disorder characterized by a deficiency in the glucocerebrosidase enzyme. Initially established as Integral Medicines, Inc., the company rebranded to Graphite Bio, Inc. in August 2020. Founded in 2017, Graphite Bio's operations are based out of its headquarters in South San Francisco, California.
株価
$22.26
最終同期: 2024-03-22
時価総額
$553.40M
変化（1日）
0.00%
変化（1年）
0.00%
国
US
取引 Graphite Bio, Inc. (GRPH)

カテゴリー

Healthcare
Graphite Bio, Inc.（GRPH）の収益
Aug 2026 時点の収益 TTM: 0
Graphite Bio, Inc. の最新の財務報告によると、現在の収益 (TTM) は 0 です。2026 年には 0 の収益があり、これは 2026 年の 0 と比較して 同等 です。収益とは、企業が商品やサービスの販売によって得る総所得です。利益とは異なり、費用は差し引かれません。
Graphite Bio, Inc. の収益履歴（2026 ～ 2026）
各年末の収益
年 収益 変化
提供された日付のデータは十分ではありません。
同業他社の収益
企業 収益 収益の差 国
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $15.74B -
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $2.23B -
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH